Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
---|
06/17/2010 | US20100150920 System and Method for Identifying Biomarkers in Ocular Fluid That Are Indicative of Ocular Disease |
06/17/2010 | US20100150919 Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
06/17/2010 | US20100150918 Cross-species-specific binding domain |
06/17/2010 | US20100150917 Method of Depleting Regulatory T Cell |
06/17/2010 | US20100150916 huTNFR1 Selective Antagonists |
06/17/2010 | US20100150915 Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
06/17/2010 | US20100150914 Agonist trkb antibodies and uses thereof |
06/17/2010 | US20100150913 Organic compounds |
06/17/2010 | US20100150912 Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
06/17/2010 | US20100150911 Methods and systems of treating age-related macular-degeneration |
06/17/2010 | US20100150910 Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for treatment of certain cancers |
06/17/2010 | US20100150909 PTHrP-DERIVED MODULATORS OF SMOOTH MUSCLE PROLIFERATION |
06/17/2010 | US20100150908 Affinity matured CRIg variants |
06/17/2010 | US20100150907 Pro115 antibody compositions and methods of use |
06/17/2010 | US20100150906 Antibodies |
06/17/2010 | US20100150905 Kim-1 antibodies for treatment of th2-mediated conditions |
06/17/2010 | US20100150904 Binding members for ige molecules |
06/17/2010 | US20100150903 Method for Treating Oncological Diseases |
06/17/2010 | US20100150902 Anti-cd151 antibodies and their use in the treatment of cancer |
06/17/2010 | US20100150901 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor |
06/17/2010 | US20100150868 Methods of Individually Optimizing Treatment for an Inflammation Associated Disease |
06/17/2010 | US20100150864 Antibodies that bind to il-18 and methods of purifying the same |
06/17/2010 | US20100150863 Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer |
06/17/2010 | US20100150862 Methods of modulating maternal-fetal tolerance |
06/17/2010 | US20100150861 Compostions with enhanced bioavailability and fast acting inhibitor or gastric acid secretion |
06/17/2010 | US20100150837 ANTIBODIES AGAINST GPIb alpha |
06/17/2010 | US20100150829 Antibodies to IL-6 and use thereof |
06/17/2010 | US20100150827 Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer |
06/17/2010 | DE102008061522A1 Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung Use of Flt3-ligand for the reinforcement of immune responses in RNA-immunization |
06/17/2010 | CA2747180A1 Use of flt3 ligand for enhancing immune responses in rna immunization |
06/17/2010 | CA2746690A1 Mixing lyophilised meningococcal vaccines with non-hib vaccines |
06/17/2010 | CA2746579A1 Mixing lyophilised meningococcal vaccines with d-t-pa vaccines |
06/17/2010 | CA2746334A1 Remedies for pemphigus containing anti fas ligand antibodies |
06/17/2010 | CA2746124A1 Methods and systems for inducing immunologic tolerance to non-self antigens |
06/17/2010 | CA2745938A1 Antibody formulation |
06/17/2010 | CA2745849A1 Novel human endogenous retorviral erv3 variant and uses thereof for diagnosing ovarian cancer |
06/17/2010 | CA2745330A1 Compound, medicament, vaccine composition and nanocapsules |
06/17/2010 | CA2745096A1 Immunostimulatory oligonucleotides |
06/17/2010 | CA2744754A1 Ige ch3 peptide vaccine |
06/17/2010 | CA2744512A1 Isoform specific anti-her4 antibodies |
06/17/2010 | CA2744510A1 Method for obtaining an excipient-free antibody solution |
06/17/2010 | CA2744035A1 Vaccine for the prevention of breast cancer recurrence |
06/17/2010 | CA2743768A1 Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
06/17/2010 | CA2740341A1 Anti-igf antibodies |
06/16/2010 | EP2196541A1 Anti-glypican-3 antibody having improved kinetics in plasma |
06/16/2010 | EP2196532A1 Use of a new isolate of neospora caninum for the development of diagnostic tests and for preparation of products for treatment and prevention of the infection caused by neospora |
06/16/2010 | EP2196476A1 Antibody formulation |
06/16/2010 | EP2196474A2 Therapeutic targets in cancer |
06/16/2010 | EP2196473A1 Mycobacterial antigens expressed during latency |
06/16/2010 | EP2196472A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
06/16/2010 | EP2196220A1 Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient |
06/16/2010 | EP2196219A1 Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
06/16/2010 | EP2196218A2 Use of anti-TNFalpha antibodies and another drug |
06/16/2010 | EP2196217A1 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
06/16/2010 | EP2196216A1 New vaccine composition and use of surfactants as immuno-adjuvant |
06/16/2010 | EP2196215A1 Method for making an immunogenic composition with Hoc fusion proteins and Soc fusion proteins |
06/16/2010 | EP2196214A1 Method for making an immunogenic composition with Hoc fusion proteins and/or Soc fusion proteins |
06/16/2010 | EP2196213A1 Immunogenic LHRH compositions and methods relating thereto |
06/16/2010 | EP2196212A1 Preparation and method of administering vaccine and iontophoresis device using the preparation |
06/16/2010 | EP2196209A1 Ctl inducer composition |
06/16/2010 | EP2196202A1 Inflammation-inhibiting compounds Lys-Pro-Thr and Lys-Pro |
06/16/2010 | EP2196196A1 Compound, medicament, vaccine composition and nanocapsules |
06/16/2010 | EP2195347A1 Method for treating and diagnosing hematologic malignancies |
06/16/2010 | EP2195339A2 A process for producing hepcidin |
06/16/2010 | EP2195028A2 Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof |
06/16/2010 | EP2195027A1 Methods of treating neurological autoimmune disorders with cyclophosphamide |
06/16/2010 | EP2195026A2 Method for inhibiting bone resorption |
06/16/2010 | EP2195025A1 Therapeutic antibody purification method and method of use |
06/16/2010 | EP2195024A1 Method of inhibiting complement activation with factor bb specific antibodies |
06/16/2010 | EP2195023A1 Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
06/16/2010 | EP2195022A1 Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
06/16/2010 | EP2195021A1 A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi |
06/16/2010 | EP2195020A1 Inactivated influenza vaccine |
06/16/2010 | EP2195019A1 Method of eliciting an immune response against pandemic influenza virus |
06/16/2010 | EP2195018A1 Novel polysaccharide immunogens from clostridium difficile |
06/16/2010 | EP2195016A1 Vaccine for the treatment of osteoarthritis |
06/16/2010 | EP2195015A1 COMPOSITION FOR TREATING PROSTATE CANCER (PCa) |
06/16/2010 | EP1560594B1 Antigenic compositions for immunization of non-human mammals against streptococcus equi |
06/16/2010 | EP1364010B1 Immunomodulatory polynucleotides and methods of using the same |
06/16/2010 | EP1234024B2 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus |
06/16/2010 | EP0938320B1 Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer |
06/16/2010 | CN1997389B Needle-free administration of FeLV vaccines |
06/16/2010 | CN1768140B A high-troughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS) |
06/16/2010 | CN1709505B Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine |
06/16/2010 | CN1582333B Live vaccine and method of manufacture |
06/16/2010 | CN1543338B Chitin microparticles and their medical uses |
06/16/2010 | CN1518558B Peptides and/or proteins and use thereof for production of therapeutic and/or prophylactic medicament |
06/16/2010 | CN1512894B Monocyte specific particulate delivery carrier |
06/16/2010 | CN1500095B Polymer conjugates of neublastin and methods of using ssame |
06/16/2010 | CN1487996B Transgenic transchromosomal rodents for making human antibodies |
06/16/2010 | CN1406249B Enhancing the circulating half-life of antibody-based fusion proteins |
06/16/2010 | CN101743473A Method for detection or treatment of graft versus host disease |
06/16/2010 | CN101743256A an anti-cancer cytotoxic monoclonal antibody |
06/16/2010 | CN101743255A an anti-cancer cytotoxic monoclonal antibody |
06/16/2010 | CN101743254A Antigen binding proteins that bind PAR-2 |
06/16/2010 | CN101743251A Peptides with anitfungal activity |
06/16/2010 | CN101743019A Bacterial extract for digestive or urinary tract disorders and process for its preparation |
06/16/2010 | CN101743018A Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis |
06/16/2010 | CN101743016A Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis |
06/16/2010 | CN101736017A Classical swine fever virus E2 subunit vaccine and preparation thereof |